{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:09:01Z","timestamp":1783512541714,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gilead Sciences","award":["IN-US-337-1910"],"award-info":[{"award-number":["IN-US-337-1910"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Oral direct-acting antiviral (DAA) treatment leads to &gt;95% sustained virological response (SVR) and could be clinically useful in regression of liver fibrosis in chronic hepatitis C virus (HCV) infection. We evaluated if ledipasvir\/sofosbuvir or sofosbuvir\u200a+\u200aribavirin is associated with regression of fibrosis in HCV patients who achieved SVR.<\/jats:p>\n            <jats:p>In this prospective cohort study performed at 3 sites in Japan, patients with genotype 1 and genotype 2 were given standard treatment of ledipasvir 90\u200amg\/sofosbuvir 400\u200amg and sofosbuvir 400\u200amg\u200a+\u200a200\u20131000\u200amg\/day ribavirin, respectively, for 12\u200aweeks. Liver fibrosis was assessed using Mac-2-binding protein glycosylation isomer (M2BPGi) and other fibrosis markers (platelet count, Fib-4 index, liver stiffness measurement [LSM]) in patients who achieved SVR.<\/jats:p>\n            <jats:p>A total of 98.1% of (n\u200a=\u200a101\/103) patients in genotype 1 cohort and 100% (n\u200a=\u200a16\/16) in the genotype 2 cohort achieved SVR12. Based on per-protocol analysis, M2BPGi levels showed a significant decrease (\u20132.2\u200a cut-off index [COI], <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001) at week 48 after treatment initiation. Forty-three patients showed a significant decrease in Fib-4 index (\u20131.2, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001), and 44 patients showed improvement in LSM (\u20135.9\u200akPa, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001).<\/jats:p>\n            <jats:p>Achievement of SVR after antiviral therapy was associated with fibrosis regression. M2BPGi correlated well with LSM at week 48 after treatment initiation, supporting the sustainable benefit of HCV therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025110","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T19:31:13Z","timestamp":1616527873000},"page":"e25110","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-6632","authenticated-orcid":false,"given":"Akito","family":"Nozaki","sequence":"first","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Chuma","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hara","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Moriya","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Numata","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[{"name":"Center for Data Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Medicine, Yokohama City University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jhep.2014.07.010","article-title":"Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma","volume":"61","author":"Hoshida","year":"2014","journal-title":"J Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/hep.22007","article-title":"Acute viral hepatitis increases liver stiffness values measured by transient elastography","volume":"47","author":"Arena","year":"2008","journal-title":"Hepatology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/srep01065","article-title":"A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis","volume":"3","author":"Kuno","year":"2013","journal-title":"Sci Rep"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","article-title":"Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarkerfor assessing liver fibrosis: more than a biomarker of liver fibrosis","volume":"53","author":"Shirabe","year":"2018","journal-title":"J Gastroenterol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0399-8320(08)73994-0","article-title":"Transient elastography (FibroScan)","volume":"32","author":"De Ledinghen","year":"2008","journal-title":"Gastroenterol Clin Biol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/liv.12628","article-title":"Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment","volume":"35","author":"Kim","year":"2015","journal-title":"Liver Int"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e47715","DOI":"10.1371\/journal.pone.0047715","article-title":"Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy","volume":"7","author":"Martinez","year":"2012","journal-title":"PLoS One"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"Knop","year":"2016","journal-title":"J Viral Hepat"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/jgh.13788","article-title":"Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response","volume":"32","author":"Tada","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2893.2006.00811.x","article-title":"Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases","volume":"14","author":"Coco","year":"2007","journal-title":"J Viral Hepat"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MEG.0000000000001106","article-title":"Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response","volume":"30","author":"Kobayashi","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","article-title":"The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin","volume":"83","author":"Ogawa","year":"2009","journal-title":"Antiviral Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ajg.2017.93","article-title":"Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis b patients with advanced fibrosis","volume":"112","author":"Chon","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jgh.14277","article-title":"Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis","volume":"33","author":"Uojima","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/apt.13431","article-title":"Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C","volume":"43","author":"Ura","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/ijms17091500","article-title":"Impact of Wisteria floribunda agglutinin-positive Mac-2-binding protein in patients with hepatitis C virus-related compensated liver cirrhosis","volume":"17","author":"Hasegawa","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e0174982","DOI":"10.1371\/journal.pone.0174982","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease","volume":"12","author":"Lai","year":"2017","journal-title":"PLoS One"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s12072-016-9754-1","article-title":"Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy","volume":"10","author":"Nagata","year":"2016","journal-title":"Hepatol Int"},{"key":"R23-20250504","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22261","article-title":"M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection","volume":"32","author":"Wei","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12876-017-0618-5","article-title":"Accuracy of M2BPGi, compared with FibroScan\u00ae, in analysis of liver fibrosis in patients with hepatitis C","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00535-014-0946-y","article-title":"A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis","volume":"50","author":"Toshima","year":"2015","journal-title":"J Gastroenterol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep4.1230","article-title":"Serum autotaxin concentrations reflect changes in liver stiffness and fibrosis after antiviral therapy in patients with chronic hepatitis c","volume":"2","author":"Ando","year":"2018","journal-title":"Hepatol Commun"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:26:55Z","timestamp":1746340015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025110"}},"subtitle":["A prospective observational study"],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025110","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"2020-07-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}